RIMI - Repository of the Institute for Medical Research
Institute for Medical Research
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
  •   RIMI
  • Institut za medicinska istraživanja
  • Radovi istraživača / Researchers' publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy

No Thumbnail
Authors
Jovanović, D
Jovović, D.
Mihailović-Stanojević, Nevena
Miloradović, Zoran
Dimitrijević, J
Maksić, Nebojša
Đukanović, Ljubica
Article (Published version)
Metadata
Show full item record
Abstract
Background: In this study, the effects of carvedilol, antihypertensive (alpha-beta blocker) agent with antiproliferative and antioxidative properties, on slowing down of chronic renal failure (CRF) progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy were examined. Methods: Eighty adult (24 weeks) SHR were divided into four groups: Control group: 20 SHR; ADR group: 20 SHR treated with ADR (2 mg/kg i.v. twice in 20 days); ADR-C group: 20 SHR treated with ADR and with carvedilol (30 mg/kg/day); ADR-CC group: 20 SHR treated with carvedilol and captopril (60 mg/kg/day). Systolic blood pressure was measured every two weeks, renal blood flow (RBF), mean arterial pressure (MAP) and renal vascular resistance (RVR) were determined at Weeks 6 and 12, creatinine clearance and proteinuria at Weeks -3 (see measurements), 6 and 12. The rats were sacrificed at Weeks 6 and 12 after the second ADR injection. Glomerular sclerosis, tubulointerstitial and blood vessel cha...nges were determined by semiquantitative scoring. Results: Carvedilol decreased systolic blood pressure. It decreased RVR and MAP, and increased RBF significantly. Carvedilol also significantly decreased interstitial infiltration in the early phase of the study, slowed down the development of interstitial fibrosis and tubular atrophy and decreased blood vessel changes. The hemodynamic and morphological effects of carvedilol were associated with slowing down the CRF progression as well as a mild decrease in proteinuria. Captopril addition to carvedilol improved its effects especially on prevention of tubulointerstitial changes. Conclusions: Results of this experimental study showed beneficial effect of carvedilol and its combination with captopril on CRF progression, indicating that clinical Studies are warranted.

Keywords:
adriamycin nephropathy / captopril / carvedilol / chronic renal failure progression / spontaneously hypertensive rats
Source:
Clinical Nephrology, 2005, 63, 6, 446-453
Publisher:
  • Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen

ISSN: 0301-0430

PubMed: 15960146

WoS: 000229555100005

[ Google Scholar ]
13
Handle
https://hdl.handle.net/21.15107/rcub_rimi_109
URI
http://rimi.imi.bg.ac.rs/handle/123456789/109
Collections
  • Radovi istraživača / Researchers' publications
Institution/Community
Institut za medicinska istraživanja
TY  - JOUR
AU  - Jovanović, D
AU  - Jovović, D.
AU  - Mihailović-Stanojević, Nevena
AU  - Miloradović, Zoran
AU  - Dimitrijević, J
AU  - Maksić, Nebojša
AU  - Đukanović, Ljubica
PY  - 2005
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/109
AB  - Background: In this study, the effects of carvedilol, antihypertensive (alpha-beta blocker) agent with antiproliferative and antioxidative properties, on slowing down of chronic renal failure (CRF) progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy were examined. Methods: Eighty adult (24 weeks) SHR were divided into four groups: Control group: 20 SHR; ADR group: 20 SHR treated with ADR (2 mg/kg i.v. twice in 20 days); ADR-C group: 20 SHR treated with ADR and with carvedilol (30 mg/kg/day); ADR-CC group: 20 SHR treated with carvedilol and captopril (60 mg/kg/day). Systolic blood pressure was measured every two weeks, renal blood flow (RBF), mean arterial pressure (MAP) and renal vascular resistance (RVR) were determined at Weeks 6 and 12, creatinine clearance and proteinuria at Weeks -3 (see measurements), 6 and 12. The rats were sacrificed at Weeks 6 and 12 after the second ADR injection. Glomerular sclerosis, tubulointerstitial and blood vessel changes were determined by semiquantitative scoring. Results: Carvedilol decreased systolic blood pressure. It decreased RVR and MAP, and increased RBF significantly. Carvedilol also significantly decreased interstitial infiltration in the early phase of the study, slowed down the development of interstitial fibrosis and tubular atrophy and decreased blood vessel changes. The hemodynamic and morphological effects of carvedilol were associated with slowing down the CRF progression as well as a mild decrease in proteinuria. Captopril addition to carvedilol improved its effects especially on prevention of tubulointerstitial changes. Conclusions: Results of this experimental study showed beneficial effect of carvedilol and its combination with captopril on CRF progression, indicating that clinical Studies are warranted.
PB  - Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen
T2  - Clinical Nephrology
T1  - Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy
EP  - 453
IS  - 6
SP  - 446
VL  - 63
UR  - conv_1664
ER  - 
@article{
author = "Jovanović, D and Jovović, D. and Mihailović-Stanojević, Nevena and Miloradović, Zoran and Dimitrijević, J and Maksić, Nebojša and Đukanović, Ljubica",
year = "2005",
abstract = "Background: In this study, the effects of carvedilol, antihypertensive (alpha-beta blocker) agent with antiproliferative and antioxidative properties, on slowing down of chronic renal failure (CRF) progression in spontaneously hypertensive rats (SHR) with adriamycin (ADR) nephropathy were examined. Methods: Eighty adult (24 weeks) SHR were divided into four groups: Control group: 20 SHR; ADR group: 20 SHR treated with ADR (2 mg/kg i.v. twice in 20 days); ADR-C group: 20 SHR treated with ADR and with carvedilol (30 mg/kg/day); ADR-CC group: 20 SHR treated with carvedilol and captopril (60 mg/kg/day). Systolic blood pressure was measured every two weeks, renal blood flow (RBF), mean arterial pressure (MAP) and renal vascular resistance (RVR) were determined at Weeks 6 and 12, creatinine clearance and proteinuria at Weeks -3 (see measurements), 6 and 12. The rats were sacrificed at Weeks 6 and 12 after the second ADR injection. Glomerular sclerosis, tubulointerstitial and blood vessel changes were determined by semiquantitative scoring. Results: Carvedilol decreased systolic blood pressure. It decreased RVR and MAP, and increased RBF significantly. Carvedilol also significantly decreased interstitial infiltration in the early phase of the study, slowed down the development of interstitial fibrosis and tubular atrophy and decreased blood vessel changes. The hemodynamic and morphological effects of carvedilol were associated with slowing down the CRF progression as well as a mild decrease in proteinuria. Captopril addition to carvedilol improved its effects especially on prevention of tubulointerstitial changes. Conclusions: Results of this experimental study showed beneficial effect of carvedilol and its combination with captopril on CRF progression, indicating that clinical Studies are warranted.",
publisher = "Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen",
journal = "Clinical Nephrology",
title = "Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy",
pages = "453-446",
number = "6",
volume = "63",
url = "conv_1664"
}
Jovanović, D., Jovović, D., Mihailović-Stanojević, N., Miloradović, Z., Dimitrijević, J., Maksić, N.,& Đukanović, L.. (2005). Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. in Clinical Nephrology
Dustri-Verlag Dr Karl Feistle, Deisenhofen-Muenchen., 63(6), 446-453.
conv_1664
Jovanović D, Jovović D, Mihailović-Stanojević N, Miloradović Z, Dimitrijević J, Maksić N, Đukanović L. Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy. in Clinical Nephrology. 2005;63(6):446-453.
conv_1664 .
Jovanović, D, Jovović, D., Mihailović-Stanojević, Nevena, Miloradović, Zoran, Dimitrijević, J, Maksić, Nebojša, Đukanović, Ljubica, "Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy" in Clinical Nephrology, 63, no. 6 (2005):446-453,
conv_1664 .

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About RIMI | Send Feedback

OpenAIRERCUB